
    
The genomic variant c.3140A>C p.His1047Pro rs121913279 on the PIK3CA gene is a missense mutation that results in the substitution of histidine with proline at the 1047th amino acid position. This variant has been identified in various cancer types, with a notable prevalence in breast cancer and head and neck squamous cell carcinoma (HNSCC). In a study of Indian HNSCC patients, the H1047R mutation, which is similar in position but different in the substituted amino acid, was found in a heterozygous state in 52% of the cases, and it was associated with a decreased overall survival and progression-free survival, indicating a poor prognosis for patients carrying this mutation [1]. The variant has not been reported in a homozygous state in this population, suggesting that even in a heterozygous state, it can exert a significant oncogenic effect.The PIK3CA gene encodes the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which is involved in the PI3K/AKT/mTOR signaling pathway. This pathway plays a critical role in cellular processes such as growth, proliferation, and survival. Mutations in PIK3CA can lead to the activation of this pathway, contributing to oncogenesis and cancer progression. The H1047R mutation, in particular, has been shown to induce conformational changes in the protein complex, leading to oncogenic activity [1].Selective targeting of PIK3CA mutations is crucial for cancer therapy, as the wild-type PI3Kα plays important roles in normal cellular processes. There has been progress in the development of selective inhibitors for PI3Kα with the H1047R mutation, with one such inhibitor showing promising results in preclinical models, providing tumor regressions and a clear pharmacodynamic response [2].In addition to human cancers, the H1047R mutation has also been studied in canine mammary tumors (CMTs), where it was detected in a significant proportion of benign and grade I malignant cases, suggesting a role in the early stages of tumorigenesis [3].Overall, the c.3140A>C p.His1047Pro rs121913279 variant in the PIK3CA gene is a missense mutation associated with oncogenic potential, poor prognosis in cancer patients, and is a target for selective inhibitor development. ClinVar submissions have classified this variant as pathogenic and oncogenic, reflecting its established role in cancer.

PIK3CA遺伝子上のゲノム変異c.3140A>C p.His1047Pro rs121913279は、ヒスチジンがプロリンに置換されるミスセンス変異であり、1047番目のアミノ酸位置に影響を及ぼします。この変異は、乳がんや頭頸部扁平上皮がん（HNSCC）を含むさまざまな癌タイプで確認されており、特に乳がんとHNSCCで顕著な頻度が報告されています。インドのHNSCC患者を対象とした研究では、同じ位置にあるが置換されるアミノ酸が異なるH1047R変異が、症例の52%でヘテロ接合状態で検出されました。この変異は全生存期間および無病進行生存期間の減少と関連しており、この変異を持つ患者にとって予後が悪いことを示しています[1]。この集団ではホモ接合状態での報告はなく、ヘテロ接合状態でも顕著な発がん性効果を発揮する可能性が示唆されています。

PIK3CA遺伝子は、ホスファチジルイノシトール3-キナーゼ（PI3K）のp110α触媒サブユニットをコードしており、PI3K/AKT/mTORシグナル伝達経路に関与しています。この経路は、細胞の成長、増殖、生存などの重要なプロセスにおいて重要な役割を果たします。PIK3CAの変異はこの経路を活性化し、発がんや癌の進行に寄与する可能性があります。特にH1047R変異は、タンパク質複合体に構造変化を引き起こし、発がん性活動を誘導することが示されています[1]。

PIK3CA変異を選択的に標的とすることは癌治療において重要であり、野生型PI3Kαは正常な細胞プロセスにおいて重要な役割を果たします。H1047R変異を持つPI3Kαに対する選択的阻害剤の開発が進展しており、そのうちの1つの阻害剤は前臨床モデルで有望な結果を示し、腫瘍の縮小と明確な薬力学的反応を提供しています[2]。

さらに、ヒトの癌だけでなく、H1047R変異は犬の乳腺腫瘍（CMT）でも研究されており、良性およびグレードIの悪性症例のかなりの割合で検出され、腫瘍形成の初期段階での役割が示唆されています[3]。

全体として、PIK3CA遺伝子のc.3140A>C p.His1047Pro rs121913279変異は、発がん性の可能性、癌患者における予後不良、および選択的阻害剤開発のターゲットとして関連付けられています。ClinVarへの提出では、この変異が病原性および発がん性として分類されており、癌におけるその確立された役割を反映しています。
    
## References
- [1] Ghosh A et al. (2024). "Prevalence and effect of PIK3CA H1047R somatic mutation among Indian head and neck cancer patients." Saudi journal of biological sciences, 31(8) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38873617/)
- [2] Ketcham JM et al. (2024). "Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kalpha Mutant Protein." Journal of medicinal chemistry, 67(6) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38477582/)
- [3] Seung BJ et al. (2024). "Detection of PIK3CA hotspot mutations in canine mammary tumors using droplet digital PCR: tissue validation and liquid biopsy feasibility." Scientific reports, 14(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39462049/)
- [4] Martinez-Nava GA et al. (2024). "Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis." Diagnostics (Basel, Switzerland), 14(3) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38337803/)
- [5] Hu Y et al. (2024). "mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation." Frontiers in oncology, 14() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38344201/)
- [6] Faske JB et al. (2024). "CarcSeq detection of lorcaserin-induced clonal expansion of Pik3ca H1047R mutants in rat mammary tissue." Toxicological sciences : an official journal of the Society of Toxicology, 201(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38851877/)
- [7] Bi Y et al. (2024). "An ultra-sensitive and rapid immunosensor for the onsite detection of circulating tumor DNA in breast cancer." Frontiers in bioengineering and biotechnology, 12() [PubMed](https://pubmed.ncbi.nlm.nih.gov/39070168/)
- [8] Alsugair Z et al. (2024). "Sialadenoma papilliferum-like intraductal papillary tumor with unveiling BRAF V600E and PIK3CA H1047R mutations: Case report with molecular analysis and literature review." International journal of surgery case reports, 118() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38636162/)
- [9] Smit DJ et al. (2024). "Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells." Cellular signalling, 121() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38909932/)
- [10] Gong Z et al. (2024). "Unilateral focal palmoplantar keratoderma associated with a postzygotic variant in PIK3CA and activation of the PI3K/AKT/mTOR pathway." European journal of dermatology : EJD, 34(3) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39015962/)
- [11] Miranda AX et al. (2024). "Genomic dissection and mutation-specific target discovery for breast cancer PIK3CA hotspot mutations." bioRxiv : the preprint server for biology, () [PubMed](https://pubmed.ncbi.nlm.nih.gov/38260414/)
- [12] Martens GA et al. (2024). "Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancer." ESMO open, 9(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38320429/)
- [13] Zheng S et al. (2024). "Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example." Molecular biomedicine, 5(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38616230/)
- [14] Debouki-Joudi S et al. (2024). "A novel PIK3CA hot-spot mutation in breast cancer patients detected by HRM-COLD-PCR analysis." Breast disease, 43(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38943378/)
- [15] Nieto-Coronel T et al. (2024). "PI3K Mutation Profiles on Exons 9 (E545K and E542K) and 20 (H1047R) in Mexican Patients With HER-2 Overexpressed Breast Cancer and Its Relevance on Clinical-Pathological and Survival Biological Effects." International journal of breast cancer, 2024() [PubMed](https://pubmed.ncbi.nlm.nih.gov/39444377/)

    
## ClinVar Submissions
- **[RCV001836707](https://www.ncbi.nlm.nih.gov/clinvar/RCV001836707/)**: Overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes
- **[RCV000024621](https://www.ncbi.nlm.nih.gov/clinvar/RCV000024621/)**: CLOVES syndrome
- **[RCV001092442](https://www.ncbi.nlm.nih.gov/clinvar/RCV001092442/)**: not provided
- **[RCV000201231](https://www.ncbi.nlm.nih.gov/clinvar/RCV000201231/)**: PIK3CA related overgrowth syndrome
- **[RCV000438435](https://www.ncbi.nlm.nih.gov/clinvar/RCV000438435/)**: Neoplasm
- **[RCV000487449](https://www.ncbi.nlm.nih.gov/clinvar/RCV000487449/)**: Rosette-forming glioneuronal tumor
- **[RCV000626894](https://www.ncbi.nlm.nih.gov/clinvar/RCV000626894/)**: Macrodactyly of toe (and 1 more)
- **[RCV000987367](https://www.ncbi.nlm.nih.gov/clinvar/RCV000987367/)**: Cowden syndrome 1
- **[RCV001253236](https://www.ncbi.nlm.nih.gov/clinvar/RCV001253236/)**: Megalencephaly-capillary malformation-polymicrogyria syndrome
- **[RCV001526597](https://www.ncbi.nlm.nih.gov/clinvar/RCV001526597/)**: Hemihypertrophy
- **[RCV001526648](https://www.ncbi.nlm.nih.gov/clinvar/RCV001526648/)**: Congenital macrodactylia
- **[RCV001705589](https://www.ncbi.nlm.nih.gov/clinvar/RCV001705589/)**: Segmental undergrowth associated with mainly venous malformation with capillary component
- **[RCV001705590](https://www.ncbi.nlm.nih.gov/clinvar/RCV001705590/)**: Segmental undergrowth associated with lymphatic malformation
- **[RCV001729349](https://www.ncbi.nlm.nih.gov/clinvar/RCV001729349/)**: CLAPO syndrome
- **[RCV001807727](https://www.ncbi.nlm.nih.gov/clinvar/RCV001807727/)**: Megalencephaly-capillary malformation-polymicrogyria syndrome

    